The key issue for MedPredict’s Thought
Leader Panel was switching: How long should anti-TNF therapy be tried? What comes next? And what would challenge anti-TNF therapy for
1st-line usage? Also discussed: developing
commercial issues, new mechanisms, unmet needs. Learn More. [1]